查詢結果分析
相關文獻
- 骨質疏鬆症的藥物治療
- 第一型介白質受體對抗劑和腫瘤壞死因子結合蛋白對去卵巢後骨質減少的效果
- 第六型介白質對造骨細胞分化的影響
- Interleukin-1α Stimulates Osteoclast Formation from Peripheral Blood Monocytes and Increases Osteoclastic Activity
- 骨質疏鬆症的藥物治療
- 藥物相關顎骨壞死--文獻回顧
- 治療骨質疏鬆藥品之簡介
- Effects of Alendronate on Bone Turnover Markers in Early Postmenopausal Women
- 骨質疏鬆症與運動之關係
- 利用超音波技術來評估骨質疏鬆症
頁籤選單縮合
| 題 名 | 骨質疏鬆症的藥物治療=Pharmacotherapy of Osteoporosis |
|---|---|
| 作 者 | 余傑明; 吳岱穎; 楊榮森; 廖振焜; 樓亞洲; 陳建志; | 書刊名 | 臺灣老年醫學暨老年學雜誌 |
| 卷 期 | 7:2 2012.05[民101.05] |
| 頁 次 | 頁77-90 |
| 分類號 | 415.596 |
| 關鍵詞 | 骨質疏鬆症; 骨吸收; 骨生成; Osteoporosis; Bone resorption; Bone formation; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 骨質疏鬆症為骨密度減少及骨組織結構破壞而導致骨骼脆弱及容易骨折之骨骼疾病。骨質疏鬆症好發於停經後婦女及年長者,所引起的骨折最常發生於脊椎、髖骨及遠端橈骨(腕部)等部位。骨折可能引起失能,造成生活品質降低、乃至增加死亡率,因此預防及治療骨質疏鬆實為現今高齡化社會之重要議題。在防治骨質疏鬆症骨折時,大部分非藥物治療可藉由改善個人飲食、運動、生活型態、跌倒預防來達成,雖然很不容易,卻是不可或缺的防治措施,較諸藥物、手術等所耗費的資源也是較少的。治療骨質疏鬆症的藥物,依作用機轉的不同,一般可分為三大類:(1)抗骨流失藥物,包括:雙磷酸鹽類、荷爾蒙、雌激素受體調節劑(SERMs)、抑鈣素、RANKL單株抗體等。(2)促骨生成藥物:如副甲腺素。(3)混合作用型藥物:例如鍶鹽。本篇中將分別論述。 |
| 英文摘要 | Osteoporosis is a bone disease caused by diminished bone density and deteriorated bone structure that leads to increased risk of fragility fractures. Osteoporosis is most commonly seen in postmenopausal women and elderly people. Osteoporotic fractures, usually occurring in vertebrae, hip joint, and distal radius, may cause disability, reduce quality of life, and even increase mortality. Prevention and treatment of osteoporosis are therefore an important issue for today’s aging society.Osteoporotic fractures can be prevented by several non-pharmacological approaches, including: personal dietary improvement, exercise, lifestyle modification, and fall prevention. Although not easy, non-pharmacological approach is an indispensable part of an effective prevention program and is more cost-saving as compared to medical or surgical treatments.Medications for treating osteoporosis can be categorized into three classes according to their mechanisms:1. Antiresorptive agents such as bisphosphonates, hormones, selective estrogen receptor modulators (SERMs), calcitonin, and RANKL monoclonal antibody.2. Osteogenic agents like parathyroid hormone (PTH).3. Mixed medication like strontium ranelate.All of these medications are discussed in this paper. |
本系統中英文摘要資訊取自各篇刊載內容。